Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers

Summary

A phase I study is conducted to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), safety and pharmacokinetics (PK) profile of a single agent CKD-516 injection on a weekly schedule in patients with advanced solid cancers failed to standard therapy. The usefulness of the this regimen is evaluated by response rate, progression free survival and vascular disruption effect by Dynamic Contrast-Enhanced MRI (DCE-MRI).

Timeline

Start

2009-12

Primary completion

2011-04

Completion

2011-04

Publications

• Kim KW, Lee JM, Jeon YS, Kang SE, Baek JH, Han JK, Choi BI, Bang YJ, Kiefer B, Block KT, Ji H, Bauer S, Kim C. Free-breathing dynamic contrast-enhanced MRI of the abdomen and chest using a radial gradient echo sequence with K-space weighted image contrast (KWIC). Eur Radiol. 2013 May;23(5):1352-60. doi: 10.1007/s00330-012-2699-4. Epub 2012 Nov 28.

Drugs

Indications